Ten year experience of retroperitoneal laparoscopic resection for pheochromocytomas: A dual-centre study of 72 cases.

Purpose: To evaluate the safety and efficacy of retroperitoneal laparoscopic resection in patients with pheochromocytoma in a retrospective study.

Methods: Clinical data of patients with adrenal and extra-adrenal pheochromocytomas, operated on between September 1998 and September 2008 at two institutions, including information on patient demographics, surgical procedure, complications and hospital stay were retrieved.

Results: Seventy-two retroperitoneal laparoscopic resections were performed (68 patients, 30 males/38 females).

Clinical relevance of urethral stents (Urospiral 2™) placement in patients with prostatic obstacle and concomitant high-risk surgical status or neurological diseases: a feasibility and safety study.

Aims: To review the indications and to assess the functional outcomes after placement of a new temporary urethral stent (TUS) in men with lower urinary tract dysfunction.

Methods: We retrospectively reviewed the data of men with prostate obstruction and concomitant high-risk surgical status or neurological diseases between 2006 and 2008. TUS placement was performed with Urospiral 2™ which is a temporary, non-expanding, transprostatic stent.

[Preliminary results of botulinum toxin in the treatment of benign prostatic hyperplasia].

Botulinum toxin was first used in urology in the field of neuro-urology as treatment for detrusor-sphincter dyssynergia and incontinence due to neurogenic overactive bladder. Its action has now been clearly demonstrated and it is now widely used for the treatment of neurogenic overactive bladder. Can botulinum toxin also constitute an effective treatment for benign prostatic hyperplasia (BPH)? Intraprostatic botulinum toxin injections have been shown to have a significant clinical and urodynamic efficacy by acting on both the static and dynamic components of BPH.